Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics on Track for 2008 Phase I in China

publication date: Dec 27, 2007

Sirnaomics of Rockville, MD plans to begin a Phase I trial of its lead drug candidate in China during the year 2008. The molecule, called STP601, uses an RNA interference mechanism to target neovascularization in the eye. If Sirnaomics achieves its goal of starting a trial that soon, it would be a remarkable achievement because Sirnaomics is a very young company – it was formed earlier this year – and it has not depended on in-licensing any technology to speed its forward progress. In an exclusive interview, Dr. Lu, CEO of the company, talks about the future of the company. More details...

Stock Symbol (NYSE: NVS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital